Weekly Topotecan for Recurrent Small Cell Lung Cancer - a Retrospective Anatolian Medical Oncology Group Study

Altinbas, Mustafa; Kalender, Mehmet Emin; Oven, Basak; Sevinc, Alper; Karaca, Halit; Kaplan, M. Ali; Alici, Suleyman; Arpaci, Erkan; Yildiz, Ramazan; Uncu, Dogan; Camci, Celalettin; Gumus, Mahmut

추천

검색

자료유형: 학술저널

저자정보: Altinbas, Mustafa (Medical Oncology Clinic, Diskapi Yildirim Beyazit Education and Research Hospital) Kalender, Mehmet Emin (Medical Oncology Department, Gaziantep University) Oven, Basak (Medical Oncology Clinic, Kartal Lutfu Kirdar Education and Research Hospital) Sevinc, Alper (Medical Oncology Department, Gaziantep University) Karaca, Halit (Medical Oncology Department, Erciyes University) Kaplan, M. Ali (Medical Oncology Department, Dicle University) Alici, Suleyman (Medical Oncology Unit) Arpaci, Erkan (Medical Oncology Clinic, Demetevler Oncology Hospital) Yildiz, Ramazan (Medical Oncology Department, Gazi University) Uncu, Dogan (Medical Oncology Clinic, Numune Education and Research Hospital) Camci, Celalettin (Medical Oncology Department, Gaziantep University) Gumus, Mahmut (Medical Oncology Clinic, Kartal Lutfu Kirdar Education and Research Hospital)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제13권 제6호

발행연도: 2012.1

수록면: 2,909 - 2,912 (4page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Aim: To evaluate efficacy and tolerability of topotecan treatment for recurrent small cell lung carcinoma. Patients and Methods: A total of 62 patients were evaluated retrospectively. Statistical analysis was performed using GraphPad Instat (version 3.05). Results: DFifty five of patients (89%) were male and 7 (11%) were female. Median age was $56.7{\pm}9.3$ (34-75). Forty eight of patients (80%) were extensive stage (ES) at the time of diagnosis. Fifty of the patients (80.6 Medical Oncology Clinic) were given median 5.36 cycles of cisplatin-etoposide (2-8 cycles). Time to recurrence was $15.6{\pm}6.13$ weeks in patients with limited stage (LS) and $6.3{\pm}3.82$ weeks in extensive stage (ES) (p<0.0001). Overall survival was $14.0{\pm}6.08$ months in ES and $17.9{\pm}6.88$ months in LS. The difference between two groups was statistically meaningful (p=0.0447). The overall survival of the patients was $14.8{\pm}6.43$ months (4.5-40 months). In terms of survival, there was no difference between males and females (p=0.1171). In 17 (27%) patients who were refractory to topotecan or in whom progression occurred other chemotherapies were used. Conclusion: Small cell lung cancer is chemosensitive, but recurrences occur in short time. Other chemotherapy regimens are used in progression. Topotecan is one of them. Patients who were young and in whom recurrences occur late had given better response to topotecan. Because of the retrospective nature of the study, we couldn't reach the records exactly and consequently, rate and duration of response couldn't be calculated. In recurrent SCLC topotecan is one of the treatment choices. But both hematological and non hematological side effects should be taken into consideration.

#Small cell lung cancer #recurrence #chemotherapy #topotecan #toxicity

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요